Pulmonx Corp

In a Stage 4 decline featuring persistent lower highs and lower lows, the medium-term bias remains bearish under declining EMAs and distribution volume. Short-term timing is neutral as price tightly tracks flat EMAs and is oversold, suggesting risk of a bounce. Therefore, execution is deferred with a Trim approach, awaiting stalled rallies into structural resistance.

• ↑FY26 revenue guided at $90–92 M supports growth outlook
• ↑Q2 adjusted EBITDA loss fell to $5.1 M from $8.4 M YoY
• ↓Q2 revenue declined to $22.8 M due to China distributor gap